Continuous Subcutaneous Insulin Infusion

Abstract

A tremendous amount of data suggest that near-normal glycemic control prevents or delays complications of diabetes, which has led to a dramatic increase in continuous subcutaneous insulin infusion (CSII) or insulin pump use. In this article, the data supporting CSII in type 1 diabetes is reviewed, and the advantages and disadvantages of CSII are analyzed. In addition, CSII use in specific situations is examined, including during childhood and pregnancy and while exercising. The published articles suggest that CSII provides better glycemic control than does conventional therapy and comparable to or slightly better control than multiple daily injections. The use of CSII may be especially indicated during pregnancy or for preconception care and for diabetes presenting in childhood or adolescence.

Extended Small-Dose Platelet Transfusions in Multitransfused Hemato-Oncological Patients: A Single-Center Experience

“…For example, the insulin pump helps maintain constant glucose levels, thereby decreasing complications. Another example is the DOPA pump, which prevents on-off periods among Parkinson disease patients [37]. Lower-antigen platelet doses administered at near-constant time intervals might also contribute to an evasion of the immune system, similar to the immune-modulating effects of desensitization therapies for atopic patients.…”

Insulin/weight ratio may serve as a predictor of success during insulin pump therapy in type 2 diabetes patients: a proof-of-concept study

“…Диагностика, контроль и лечение В то время как эффективность ППИИ при лечении СД1 хорошо изучена и доказана [10], целесообразность при-менения ППИИ для лечения пациентов с СД2 остается предметом споров: часть авторов указывают на значи-тельные преимущества ППИИ [11], другие остаются настроенными скептично [12], остальные утверждают, что ППИИ не уступает, но и не превосходит эффектив-ность МИИ у пациентов с СД2 [13,5]. Обсуждая вопрос о целесообразности использования ППИИ у людей с СД2, следует принимать в расчет то, что все больше людей заболевают в молодом возрасте.…”

Facilitating technology adoption in the NHS: negotiating the organisational and policy context – a qualitative study

“…However, mainstream adoption of the technology was limited, linked to concerns about efficacy and safety and the potential financial burden on the NHS. 188,189 In the past decade, technological advances have resulted in a new generation of smaller, more portable, more efficient and user-friendly pumps with additional safety features. [189][190][191] Several studies in recent years have demonstrated the benefits of IPT in type 1 diabetes compared with MDIs.…”